



Financial Tear Sheet

Corporate Profile

Rigel's current clinical programs include clinical trials of fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, in a number of indications. The company has submitted an NDA to the FDA for fostamatinib in patients with chronic or persistent ITP. The investigation of fostamatinib also includes Phase 2 clinical trials for autoimmune hemolytic anemia (AIHA) and IgA nephropathy (IgAN). In addition, Rigel has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics.

Recent News

Date	Title
08/01/17	Rigel Announces Second Quarter 2017 Financial Results and Provides Company Update
07/25/17	Rigel Announces Conference Call and Webcast to Report Second Quarter 2017 Financial Results

Stock Performance

RIGL (Common Stock)	
Exchange	NASDAQ (US Dollar)
Price	\$2.21
Change (%)	-0.06 (2.64%)
Volume	731,931
Data as of 08/17/17 4:00 p.m. ET Refresh quote	



Data provided by Nasdaq. Minimum 15 minutes delayed.

SEC Filings

Filing Date	Form
08/01/17	S-8
08/01/17	8-K

Primary IR Contact

Ryan Maynard
 CFO
 Phone: (650) 624-1284
 E-mail: invrel@rigel.com